Back to Search
PETER VOORHEES, MD
MD
Hematology (Internal Medicine) Physician
NPI: 1457412454IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
200100485(NC)
Hematology & Oncology Physician
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
200100485(NC)
Hematology (Internal Medicine) PhysicianPrimary
Internal Medicine — Hematology
Code: 207RH0000X
200100485(NC)
Education
UNIVERSITY OF MICHIGAN MEDICAL SCHOOL
Class of 1997
Research & Publications (20)
Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.
PMID 19344406·Br J Haematol·2009
4-observational
Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma.
PMID 17562254·Clin Lymphoma Myeloma·2007
6-review
Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
PMID 17975159·Clin Cancer Res·2007
8-other
The proteasome and proteasome inhibitors in cancer therapy.
PMID 16402903·Annu Rev Pharmacol Toxicol·2006
6-review
Emerging role of novel combinations for induction therapy in multiple myeloma.
PMID 16879768·Clin Lymphoma Myeloma·2006
6-review
Follicular lymphoma with a burkitt translocation--predictor of an aggressive clinical course: a case report and review of the literature.
PMID 14736281·Arch Pathol Lab Med·2004
5-case
Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.
PMID 18668698·Hematol Oncol·2009
3-trial
Direct growth of compound semiconductor nanowires by on-film formation of nanowires: bismuth telluride.
PMID 19588906·Nano Lett·2009
8-other
Direct measurement of dopant distribution in an individual vapour-liquid-solid nanowire.
PMID 19421218·Nat Nanotechnol·2009
8-other
Three-dimensional analysis of solid oxide fuel cell Ni-YSZ anode interconnectivity.
PMID 19144260·Microsc Microanal·2009
8-other
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
PMID 19050304·Blood·2009
8-other
A case of hook effect in the serum free light chain assay using the Olympus AU400e.
PMID 18996106·Clin Biochem·2009
5-case
Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.
PMID 18765533·Clin Cancer Res·2008
8-other
Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.
PMID 18305219·Blood·2008
8-other
Malignant insulinoma: a rare presentation of a rare tumor.
PMID 17719587·Gastrointest Endosc·2007
5-case
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
PMID 17591945·Blood·2007
4-observational
Coarsening of bicontinuous structures via nonconserved and conserved dynamics.
PMID 17358326·Phys Rev E Stat Nonlin Soft Matter Phys·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 5 locations total
- Address
- 945 N 5TH ST
ALBEMARLE, NC 28001 - Phone
- (980) 323-7790
Locations (5)
Practice Location
945 N 5TH ST, ALBEMARLE, NC
(980) 323-7790
Practice Location
1021 MOREHEAD MEDICAL DR, CHARLOTTE, NC
(980) 442-2000
Practice Location
4525 CAMERON VALLEY PKWY, CHARLOTTE, NC
(704) 302-8300
Practice Location
100 MEDICAL PARK DR, CONCORD, NC
(704) 403-1370
Practice Location
1550 FAULK ST, MONROE, NC
(980) 442-0430
Quick Facts
- NPI
- 1457412454
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 5
- Years in Practice
- 29
- Publications
- 20
Are you this provider?
Claim Your Profile